BioSpace

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

Par BioSpace

1 minute de lecture
Partager
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Vous avez une actualité à partager avec le secteur événementiel ?

Envoyez un communiqué de presse ou une information et touchez des milliers de professionnels de l'événementiel.

Nous contacter→

Plus dans Health Tech

Articles connexes